Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
PSA for anyone that chased me down the BPMC rabbit hole:

Deciphera might cause some waves.

And that is ok.


BPMC data in 4L:
In 56 patients with PDGFRa D842V-driven GIST, tumor reduction was observed in 98% of patients, with 5 complete response and 42 partial response (ORR of 84%). The 12-month DoR was 76.3%, and the 12-month progression free survival rate was 81.3%.
https://www.biospace.com/article/releases/avapritinib-receiv...

DCPH data:
disease control rate @ 3 months 66%.
mPFS: 24 weeks
https://investors.deciphera.com/static-files/fd21de46-7d32-4...

Deciphera looks ok, but not better than BPMC currently. The TIE2 inhibitor looks too early to make a call. If data is positive for their GIST treatment and their TIE2 inhibitor, I'd be curious. Right now, I dont think its going to make a serious run at BPMC.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.